The company is hosting a conference call and webcast to provide regulatory updates on its clinical development program for nomlabofusp, indicating transparency and engagement with stakeholders. This ...

The Dominican Republic wants jewelers to love larimar, the national stone. But authorities shut the mine temporarily after two fatal accidents. The inspiration for Joarla Caridad’s Pool Ring with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication entitled ...

Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had remained in part on the program since 2021. The rare disease biotech can now ...

As of December 31, 2025, the Company had cash, cash equivalents and marketable securities totaling $136.9 million. Together with net proceeds of approximately $107.6 million from the February 2026 ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Larimar Therapeutics held its breath for over a year, but the FDA has finally given the biotech a green light to continue trials of its lead, and only, asset this year. To coincide with its ...

Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading sharply higher Tuesday after the company said the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its ...

Oppenheimer sets Larimar Therapeutics' price target at $26, anticipating $1.2 billion in global revenues by 2030. The company aims for FDA marketing application submission in late 2025, focusing on ...

Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s ...

BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...